Condition: Sickle Cell Disease
Interventions: Drug: Azithromycin; Other: Placebo
Sponsor: Vanderbilt University
Recruiting – verified November 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease.
| Related Articles |
Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease.
Cochrane Database Syst Rev. 2014 Aug 2;8:CD003733
Authors: Knight-Madden JM, Hambleton IR
Abstract
BACKGROUND: Bronchodilators are used to treat bronchial hyper-responsiveness in asthma. Bronchial hyper-responsiveness may be a component of acute chest syndrome in people with sickle cell disease. Therefore, bronchodilators may be useful in the treatment of acute chest syndrome.
OBJECTIVES: To assess the benefits and risks associated with the use of bronchodilators in people with acute chest syndrome.
SEARCH METHODS: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. Additional searches were carried out on MEDLINE (1966 to 2002) and Embase (1981 to 2002).Date of the most recent search of the Group’s Haemoglobinopathies Trials Register: 17 March 2014.
SELECTION CRITERIA: Randomised or quasi-randomised controlled trials. Trials using quasi-randomisation methods will be included in future updates of this review if there is sufficient evidence that the treatment and control groups are similar at baseline.
DATA COLLECTION AND ANALYSIS: We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.
MAIN RESULTS: We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.
AUTHORS’ CONCLUSIONS: If bronchial hyper-responsiveness is an important component of some episodes of acute chest syndrome in people with sickle cell disease, the use of inhaled bronchodilators may be indicated. There is need for a well-designed, adequately-powered randomised controlled trial to assess the benefits and risks of the addition of inhaled bronchodilators to established therapies for acute chest syndrome in people with sickle cell disease.
PMID: 25086371 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Goodwin dealing with Sickle Cell, asthma – wivb.com
|
Goodwin dealing with Sickle Cell, asthma
wivb.com Since he was little, Goodwin has battled asthma, along with the sickle cell trait, which makes it difficult to breathe from time to time. “I get half the oxygen to my blood, than normal people,” said Goodwin. It is something he has to monitor … |
View full post on asthma – Google News
Respiratory syncytial virus and seasonal influenza cause similar illnesses in children with sickle cell disease.
| Related Articles |
Respiratory syncytial virus and seasonal influenza cause similar illnesses in children with sickle cell disease.
Pediatr Blood Cancer. 2014 Jan 31;
Authors: Sadreameli SC, Reller ME, Bundy DG, Casella JF, Strouse JJ
Abstract
BACKGROUND: Respiratory syncytial virus (RSV) is a cause of acute chest syndrome (ACS) in sickle cell disease (SCD), but its clinical course and acute complications have not been well characterized. We compared RSV to seasonal influenza infections in children with SCD.
PROCEDURE: We defined cases as laboratory-confirmed RSV or seasonal influenza infection in inpatients and outpatients <18 years of age with SCD from 1 September 1993 to 30 June 2011. We used Fisher’s exact test to compare proportions, Student’s t-test or Wilcoxon rank-sum test to compare continuous variables, and logistic regression to evaluate associations.
RESULTS: We identified 64 children with RSV and 91 with seasonal influenza. Clinical symptoms, including fever, cough, and rhinorrhea were similar for RSV and influenza, as were complications, including ACS and treatments for SCD. In a multivariable logistic regression model, older age (OR 1.2 per year, 95% CI [1.02-1.5], P?=?0.04), increased white blood cell count at presentation (OR 1.1 per 1,000/?l increase, 95% CI [1.03-1.3], P?=?0.008), and a history of asthma (OR 7, 95% [CI 1.3-37], P?=?0.03) were independently associated with increased risk of ACS in children with RSV. The hospitalization rate for children with SCD and RSV (40 per 1,000 <5 years and 63 per 1,000 <2 years) greatly exceeds the general population (3 in 1,000 <5 years).
CONCLUSIONS: We conclude that RSV infection is often associated with ACS and similar in severity to influenza infection in febrile children with SCD. Pediatr Blood Cancer 2014;9999:1-4. © 2014 Wiley Periodicals, Inc.
PMID: 24481883 [PubMed – as supplied by publisher]
View full post on pubmed: asthma